Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.56 |
| ▸ | CDK4 | P11802 | 8/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.56 |
| ▸ | CCND1 | P24385 | 8/20 | 0.56 |
| ▸ | CCND3 | P30281 | 8/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.51 |
| ▸ | TYK2 | P29597 | 3/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | ITK | Q08881 | 3/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17251722 | 0.85 | CDK2 (0.53) | CDK2CDK4CCNA2CCND1CCND3 | |
| SCHEMBL17251750 | 0.81 | MAPT (0.50) | BRD4JAK2TYK2JAK1FYN | |
| SCHEMBL30222327 | 0.81 | FGFR1 (0.68) | CDK2CDK4CCNA2CCND1CCND3 | |
| SCHEMBL17251702 | 0.78 | BRD4 (0.38) | CDK2CDK4CCNA2CCND1CCND3 | |
| SCHEMBL18562045 | 0.77 | CDK2 (0.53) | CDK2CDK4CCNA2CCND1CCND3 | |
| SCHEMBL18576291 | 0.75 | CDK2 (0.48) | CDK2CDK4CCNA2CCND1CCND3 | |
| SCHEMBL5952843 | 0.75 | CDK2 (0.64) | CDK2CDK4CCNA2CCND1CCND3 | |
| SCHEMBL5952685 | 0.75 | FGFR1 (0.63) | CDK2CDK4CCNA2CCND1CCND3 | |
| SCHEMBL5508107 | 0.72 | CDK4 (0.60) | CDK2CDK4CCNA2CCND1CCND3 | |
| SCHEMBL5952268 | 0.72 | FGFR1 (0.67) | CDK2CDK4CCNA2CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708164-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3139919-B1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-9981915-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981915-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | CDK2 298/4885CDK4 197/4885CCNA2 700/4885 |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | CDK2 298/4885CDK4 197/4885CCNA2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.